Ixazomib (MLN2238) is a potent, selective, and reversible proteasome inhibitor that targets the chymotrypsin-like β5 subunit of the 20S proteasome with an IC50 of 3.4 nM (Ki = 0.93 nM). It is the biologically active form of the prodrug MLN9708, formed via hydrolysis in plasma. It demonstrates high selectivity for the β5 subunit over β1 and β2 subunits and shows antiproliferative activity in various cancer cell lines. It inhibits osteoclastogenesis and reduces tumor growth in xenograft models. Reagent grade, for research use only.
Usually ships within 24 hours.